Sana Biotechnology ( NASDAQ: SANA) was upgraded to Market Outperform from Market Perform at Citizens as the research broker ...

Sana Biotechnology (NASDAQ:SANA – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a ...

Fintel reports that on March 18, 2025, Citizens Capital Markets upgraded their outlook for Sana Biotechnology (NasdaqGS:SANA) ...

Reports cash equivalents, and marketable securities as of December 31, were $152.5M compared to $205.2M as of December 31, 2023. The decrease ...

Citizens Jmp upgraded shares of Sana Biotechnology (NASDAQ:SANA – Free Report) from a market perform rating to an outperform rating in a report issued on Tuesday, Marketbeat reports. They currently ...

SEATTLE (AP) — SEATTLE (AP) — Sana Biotechnology Inc. (SANA) on Monday reported a loss of $49.1 million in its fourth quarter. The Seattle-based company said it had a loss of 21 cents per share.

Fintel reports that on March 18, 2025, Citizens Capital Markets upgraded their outlook for Sana Biotechnology (NasdaqGS:SANA) from Market Perform to Market Outperform. As of March 4, 2025 ...

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells ...

This compares with -$88.12 million, or -$0.45 per share, last year. Excluding items, Sana Biotechnology, Inc. reported adjusted earnings of -$54.79 million or -$0.23 per share for the period.